Market Overview

Corindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 Conference

Share:

Breakfast symposium and immersive booth activities highlight
capabilities of vascular robotic technology and importance of remote
access to care

Corindus
Vascular Robotics
, Inc. (NYSE:CVRS), a leading developer
of precision vascular robotics, will feature its CorPath® GRX
System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018
Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX
is the first FDA-cleared medical device for robotic-assisted vascular
interventions. The company will showcase its revolutionary technology
throughout the conference through live cases and presentations, during a
Corindus-sponsored breakfast symposium, and at Booth 421.

On Sunday, September 23, 2018 from 6:30 a.m. – 8:00 a.m., Corindus'
Cardiovascular Chief Medical Officer, Dr. J. Aaron Grantham of St.
Luke's Hospital of Kansas City, will chair the breakfast symposium, "New
Frontiers in Robotic Interventions: Current and Future Technology." The
agenda will include the following topics:

  • "New Clinical Evidence in Robotic Interventions" presented by Lawrence
    Ang, M.D.
  • "Robotics for Complex PCI: A Case Series" presented by Manish A.
    Parikh, M.D.
  • "The 1st Remote PCI from 100 Miles Away" presented by
    Ryan Madder, M.D.
  • "Building the Next Generation Robot" presented by Mitchell Krucoff,
    M.D.

Space for the breakfast symposium is limited; please register at www.tctconference.com/satelliteprograms.

"I am pleased to chair this educational program with an esteemed group
of interventionalists to highlight the current and future capabilities
of vascular robotics. There has been tremendous progress made in the
development of our robotic platform, including procedural automation and
remote technology, which we believe will have the power to change the
treatment paradigm and increase patient access to care," said J. Aaron
Grantham, M.D., Cardiovascular Chief Medical Officer of Corindus.

The CorPath GRX System will be on display at Corindus' Booth 421.
Attendees will have the opportunity to be among the first to experience
future procedural automation techniques and compete with their peers in
a wiring challenge. To schedule a hands-on demonstration of vascular
robotics with an advanced simulator, please visit www.corindus.com/TCT2018.

Transcatheter Cardiovascular Therapeutics (TCT) is the world's largest
and most important educational meeting specializing in interventional
cardiovascular medicine. For 30 years, TCT has been the center of
cutting-edge educational content, showcasing the latest advances in
current therapies and clinical research. This symposium is designed for
interventional cardiologists, radiologists, clinical cardiologists,
scientists, vascular medicine specialists, cardiac and vascular
surgeons, nurse practitioners, cath lab technicians, and other
healthcare professionals with a special interest in the field of
interventional and vascular medicine.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in
robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. During the
procedure, the interventional cardiologist sits at a radiation-shielded
workstation to advance guide catheters, stents, and guidewires with
millimeter-by-millimeter precision. The workstation allows the physician
greater control and the freedom from wearing heavy lead protective
equipment that causes musculoskeletal injuries. CorPath GRX is the
second generation robotic-assisted technology offering enhancements to
the platform by adding important key upgrades that increase precision,
improve workflow, and extend the capabilities and range of procedures
that can be performed robotically. With the CorPath System, Corindus
Vascular Robotics brings robotic precision to interventional procedures
to help optimize clinical outcomes and minimize the costs associated
with complications of improper stent placement during manual procedures.
For additional information, visit www.corindus.com,
and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical
or current facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of Corindus to be materially different from historical results or from
any future results or projections expressed or implied by such
forward-looking statements. Accordingly, readers should not place undue
reliance on any forward looking statements. In addition to statements
that explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects," "estimates,"
"intends," "anticipates" or "plans" to be uncertain and forward-looking.
Forward-looking statements may include comments as to Corindus' beliefs
and expectations as to future events and trends affecting its business
and are necessarily subject to uncertainties, many of which are outside
Corindus' control.

Examples of such statements include statements regarding or such as:

  • the tremendous progress made in the continued development of
    robotic technology, including telerobotics, which we believe will have
    the power to change the treatment paradigm and increase patient access
    to care.

Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are
described in the sections titled "Risk Factors" in the Company's filings
with the Securities and Exchange Commission, including its most recent
Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as
well as reports on Form 8-K, including, but not limited to the
following: our ability to expand our technology platform and achieve the
advances necessary for telestenting and remote procedures, including in
humans; our ability to expand our technology platform for use in other
segments of the vascular intervention market, including
neurointerventional and other more complex cardiac interventions;
obtaining necessary regulatory approvals for the use on humans and
marketing of our products in the United States and in other countries;
risks associated with market acceptance; our ability to enforce our
intellectual property rights; our need for additional funds to support
our operations; factors relating to engineering, regulatory,
manufacturing, sales and customer service challenges; and potential
safety and regulatory issues that could slow or suspend our sales.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More information
is available on Corindus' website at
http://www.corindus.com.

View Comments and Join the Discussion!